On September 17, 2026, the U.S. Food and Drug Administration held a public workshop devoted specifically to testosterone use in menopausal women. For women in Fort Myers and throughout Lee County, the event matters because it brought female-specific questions about sexual function, blood testing, dosing, and long-term safety into a formal federal discussion. The meeting was designed to examine current evidence and identify knowledge gaps that could guide future research and potential drug development. It was not the approval of a new testosterone product or a new FDA-approved indication for women.
The distinction is important for anyone seeing headlines about an “FDA review” and wondering whether treatment rules changed overnight. The FDA workshop details describe a scientific meeting organized by the Office of Women’s Health and the Center for Drug Evaluation and Research. It was not a product approval decision. FDA also opened a public docket on the risks and benefits of testosterone use in menopausal women. As of September 28, 2026, comments remain open through 11:59 p.m. Eastern Time on October 19, 2026.
What this FDA review changes—and what it does not
- The September workshop did not approve testosterone specifically for women or create a new indication.
- The clearest evidence remains focused on carefully assessed postmenopausal women with HSDD.
- Blood testing can support safe monitoring, but a testosterone number alone does not establish who needs treatment.
Considering testosterone within a broader hormone plan?
A thoughtful women’s hormone replacement therapy consultation can review symptoms, medical history, treatment goals, off-label considerations, and appropriate monitoring before decisions are made.
Physician-reviewed content • Evidence-aware care • Personalized treatment planning
Put testosterone questions in the wider menopause picture
Treatment decisions often make more sense when viewed through personalized HRT planning and the cardiovascular considerations discussed in HRT and heart health.
What the FDA actually examined in September 2026
The workshop focused on a practical problem: testosterone is being used off-label in women, yet major questions remain about who might benefit, how treatment should be measured, and what long-term risks may exist. FDA highlighted sexual function, cognition, mood, and musculoskeletal health as areas where the strength of evidence differs. The agency also called attention to the difficulty of measuring testosterone accurately at female concentrations and interpreting a laboratory value in relation to symptoms. Long-term cardiovascular and breast safety were among the unresolved issues placed squarely on the agenda.
The official Federal Register notice says the workshop was intended to help inform future research and potential drug development. That wording does not mean FDA has concluded that testosterone should be approved for broad menopausal symptoms. It also does not establish that a low blood level alone identifies a condition that should be treated.
Why the workshop is different from a drug approval
A public workshop lets regulators, researchers, clinicians, patients, and other stakeholders discuss available science. It can also identify evidence gaps. A drug approval is different. It requires a sponsor to submit data for a specific product, dose, indication, manufacturing standard, and safety profile. The September workshop did not create a women-specific label. Patients should therefore separate the importance of the discussion from the legal status of currently available testosterone products.
Where the evidence for testosterone in women is strongest
The most established evidence concerns postmenopausal women with hypoactive sexual desire disorder, often shortened to HSDD. This diagnosis involves persistent or recurrent low sexual desire that causes personal distress and is not better explained by another factor that should be addressed first. A major international consensus statement and the ISSWSH clinical guideline support carefully selected systemic transdermal testosterone use for women with HSDD after a full biopsychosocial assessment. The guideline describes the benefit as moderate and emphasizes informed consent because treatment in the United States is off-label.
That evidence does not automatically extend to every symptom that appears during menopause. The FDA workshop specifically identified open questions involving mood, cognition, frailty, sleep, and musculoskeletal health. Existing consensus guidance has not established testosterone as a general treatment for memory problems, depressed mood, overall well-being, bone protection, or broad “anti-aging” goals. Fatigue, sleep disruption, low mood, and reduced strength can have multiple causes. Evaluation should not assume testosterone is the missing piece.
Sexual desire is not the same as a laboratory number
HSDD is a clinical diagnosis, not a diagnosis made from a single testosterone result. Sexual desire can be affected by vaginal discomfort, medications, relationship factors, stress, depression, other medical conditions, and changes in estrogen status. Symptoms, distress, health history, and the broader context therefore matter as much as a hormone panel when deciding what to evaluate or treat.
A symptom review matters more than a single number
When low desire, sleep changes, fatigue, mood concerns, or other menopausal symptoms overlap, a women’s hormone therapy evaluation can help separate potentially relevant hormone issues from other factors that may need attention.
Why testosterone blood tests need careful interpretation
Women have much lower testosterone concentrations than men, which can make accurate measurement more challenging. Assays may differ in accuracy at female concentrations, and reference ranges can vary by laboratory. Clinical guidance does not support using a total testosterone value to diagnose HSDD or to decide that treatment is needed simply because a result is near the lower end of a range. A baseline level can still help identify an unexpectedly high starting concentration. It also creates a reference for later safety monitoring.
Testing has a different purpose after therapy begins. The goal is not to chase a number in hopes that a higher level will produce a better response. Monitoring helps limit excessive exposure while symptoms and side effects are reviewed at the same time. A result above the laboratory’s physiologic premenopausal range may call for dose adjustment even when the patient feels well.
What different parts of an evaluation can tell you
No single test answers every question about testosterone use in menopause. The most useful information comes from combining symptoms, medical history, medication review, examination when appropriate, and targeted laboratory monitoring.
| Evaluation point | What it can help clarify | What it cannot establish by itself |
|---|---|---|
| Sexual desire and distress history | Whether low desire is persistent, bothersome, and consistent with HSDD features | Whether testosterone is automatically the right treatment |
| Medication and health review | Potential contributors such as medicines, medical conditions, or other menopausal symptoms | A hormone dose without considering the rest of the clinical picture |
| Baseline total testosterone | Whether the starting concentration is unexpectedly high and a reference for monitoring | A diagnosis of HSDD or a universal treatment threshold |
| Follow-up testosterone testing | Whether exposure is staying within the laboratory’s physiologic premenopausal range | Whether a higher result will produce more benefit |
| Side-effect review | Signs of androgen excess such as acne, increased facial or body hair, or scalp hair thinning | Long-term cardiovascular or breast safety |
| Response over time | Whether sexual desire and related distress are meaningfully improving | A reason to continue indefinitely without reassessment |
Dosing is a female-specific safety issue
One of the central practical problems is that FDA-approved testosterone products in the United States are not approved for use in women. Clinical guidance therefore discusses off-label use of products originally manufactured for male dosing when a clinician determines that treatment is appropriate. The doses used for women are substantially lower, and the aim is to keep testosterone exposure within the physiologic premenopausal range rather than to reproduce male concentrations. This is why simply applying a standard male dose would be inappropriate.
The ISSWSH guideline notes that, when no approved female formulation is available, approximately one-tenth of a standard male dose of a 1% transdermal product can often produce female-range exposure. That statement is professional guidance, not a do-it-yourself dosing instruction. Product concentration, application method, absorption, baseline values, symptoms, and follow-up all matter. Internet formulas are not substitutes for individualized prescribing. Patients should not divide, adjust, or escalate testosterone on their own to push a blood level higher.
Monitoring matters after treatment starts
The same guideline recommends checking total testosterone before treatment and again several weeks after initiation so excessive exposure can be identified and the dose can be adjusted. Stable levels still require periodic monitoring along with assessment for clinical benefit and androgen-related side effects. Acne, increased facial or body hair, and scalp hair thinning can signal excessive androgen effect, while voice changes are a more concerning potential effect. Lack of meaningful improvement should prompt reassessment rather than automatic dose escalation.
The biggest unanswered question is long-term safety
Shorter-term randomized trials at physiologic female doses have not shown a signal of serious adverse events in the selected women studied. Those findings have important limits. Major consensus guidance notes that many trials excluded women with higher cardiometabolic risk. Long-term safety data are limited beyond about 24 months, making firm conclusions about cardiovascular events or breast cancer risk over many years difficult. The FDA highlighted those gaps in September and emphasized the need for better long-term study designs.
Safety also depends on the individual patient, not only the drug. Medical history, cardiovascular risk factors, breast history, liver health, lipid status, current medications, and the reason for considering testosterone can affect the decision. ACOG’s menopausal hormone guidance stresses shared decision-making and notes the absence of an FDA-approved testosterone formulation for menopausal symptoms. That context is especially relevant when testosterone is discussed alongside a broader women’s hormone replacement therapy plan.
What the September review means for women considering treatment
The practical message is not that testosterone is suddenly approved for women, nor that existing evidence should be ignored. It is that federal regulators are giving focused attention to a field where clinical use, patient interest, and product regulation are not fully aligned. Women considering treatment can ask whether their symptoms match the population in which benefit has been shown, what formulation and dose would be used, how monitoring would work, and what is known or unknown about long-term safety. Those questions are more useful than asking only whether a testosterone number is “low.”
At Fountain of Youth in Fort Myers, Florida, staff stays current on developments in women’s hormone therapy and the evolving testosterone evidence so consultations can reflect the current regulatory landscape. A women’s hormone replacement therapy visit should begin with the symptoms affecting daily life, sexual health, sleep, comfort, or well-being. The review can then consider medical history, medications, and other factors that may contribute. Testosterone may be relevant for some women. It should not be treated as a universal add-on to menopause care. The FDA’s current process reinforces the need to match treatment decisions to the evidence that actually exists.
The public comment period gives patients, clinicians, researchers, and other stakeholders a formal way to contribute to the agency’s record before October 19, 2026. Comments do not function as votes for or against approval, and the workshop does not guarantee that a women-specific testosterone product will reach the U.S. market. Future approval would require an application supported by evidence that meets FDA standards for a defined use. For now, patients should expect conversations about off-label status, potential benefits, uncertainties, and follow-up.
When a focused hormone evaluation may be useful
A consultation can be useful when the decision involves more than whether a laboratory result falls inside or outside a reference range.
- You have persistent low sexual desire that causes distress and want other possible contributors evaluated before discussing testosterone.
- You are considering testosterone within menopause care and want to understand off-label use, dosing principles, monitoring, and known evidence limits.
- You are already receiving hormone therapy and need a structured review of symptoms, laboratory results, treatment response, or possible androgen-related side effects.
The appropriate next step depends on the complete clinical picture rather than a single symptom or hormone value.
Frequently Asked Questions
Did the FDA approve testosterone for women in September 2026?
No. The September 17 event was a public scientific workshop examining evidence and knowledge gaps around testosterone use in menopausal women. It did not create a new FDA-approved indication or approve a women-specific testosterone product in the United States. The meeting may help shape future research and potential drug development.
Can a low testosterone blood test prove that I need treatment?
No. Current clinical guidance does not use a total testosterone level by itself to diagnose HSDD or determine that treatment is necessary. A baseline result can be useful for safety monitoring if therapy is being considered. Symptoms, distress, health history, medications, and other possible causes of low desire still need clinical evaluation.
What benefit of testosterone has the clearest evidence in postmenopausal women?
The strongest evidence is for improving sexual desire and related sexual-function outcomes in appropriately assessed postmenopausal women with HSDD. Research does not support treating every menopausal symptom with testosterone. Evidence for cognition, mood, general well-being, and musculoskeletal outcomes remains incomplete or insufficient for broad treatment claims.
What should I ask before considering testosterone as part of hormone therapy?
Ask why testosterone is being considered, whether your symptoms fit an evidence-supported use, and whether the proposed treatment is off-label. Ask how the dose is selected, which blood tests and clinical checks will be used, and what side effects should trigger a call. It is also reasonable to ask how other menopausal symptoms are being addressed and what is known about long-term safety. Shared decision-making should include both potential benefit and the areas where evidence is still limited.
Continue exploring evidence-aware hormone care
Readers weighing longer-term treatment decisions can review what is known about extended hormone therapy and how sleep and hormonal health can fit into a broader assessment.
Questions? We are here to help! Call 239-355-3294.
Medical review: Reviewed by Dr. Keith Lafferty MD, Fort Myers on October 4, 2026. Fact-checked against government and academic sources; see in-text citations. This page follows our Medical Review & Sourcing Policy.
